Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
Study context
- Population
- Critically and noncritically ill hospitalized patients with COVID-19, hospitals in Pakistan, India and Ireland, June 2021–September 202261 critically, 89 noncritically ill
- Planned comparison
- Ivermectin vs no ivermectin
- Primary endpoint
- Respiratory and cardiovascular organ support-free days (ordinal scale; in-hospital death = −1, days free of organ support in survivors)
- Follow-up
- Day 21
Methodological detailsinternational, multifactorial, adaptive platform, Bayesian cumulative logistic model, enrollment closed for operational futility, Enrollment closed for operational futility, following external evidence of no benefit with ivermectin in nonhospitalized COVID-19 patients
- International
- Multifactorial
- Adaptive platform
- Bayesian cumulative logistic model
- Enrollment closed for operational futility
- Enrollment closed for operational futility, following external evidence of no benefit with ivermectin in nonhospitalized COVID-19 patients
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP). Crit Care Med. Published 8 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →